Immune and other responses to viral infections

Nutrition Reviews

Volumn 58, Issue 2 II, 2000, Pages

  Ploegh, Hidde L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ADENOVIRUS; ANTIGEN EXPRESSION; CONFERENCE PAPER; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; HERPES VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; VIRUS CELL INTERACTION; VIRUS INFECTION;

ADENOVIRIDAE; CYTOMEGALOVIRUS; HERPES; HERPESVIRIDAE; HUMAN HERPESVIRUS 4; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0034116233     PISSN: 00296643     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1753-4887.2000.tb07800.x     Document Type: Conference Paper

References (67)

1. Townsend A, Bodmer H. Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol 1989;7:601-24
2. Brodsky FM, Lem L, Solache A, Bennett EM. Human pathogen subversion of antigen presentation. Immunol Rev 1999;168:199-215
3. Doherty P. Immunity to viruses. Immunologist 1995; 3:231-3
4. Guidotti LG, Chisari FV. To kill or to cure: options in host defense against viral infection. Curr Opin Immunol 1996;8:478-83
5. David-Watine B, Israel A, Kourilsky P. The regulation and expression of MHC class I genes. Immunol Today 1990;11:286-92
6. Hayder H, Mullbacher A. Molecular basis of immune evasion strategies by adenoviruses. Immunol Cell Biol 1996;74:504-12
7. Ploegh HL. Viral strategies of immune evasion. Science 1998;280:248-53
8. Heemels MT, Ploegh H. Generation, translocation, and presentation of MHC class I-restricted peptides. Annu Rev Biochem 1995;64:463-91
9. Rock KL, Goldberg AL. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol 1999;17:739-79
10. Bjorkman PJ, Saper MA, Samraoui B, et al. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987;329:506-12
11. Williams DB, Watts TH. Molecular chaperones in antigen presentation. Curr Opin Immunol 1995;7:
12. Hughes EA, Cresswell P. The thiol oxidoreductase ERp57 is a component of the MHC class I peptide-loading complex. Curr Biol 1998;8:709-12
13. Lindquist JA, Jensen ON, Mann M, Hammerling GJ. ER-60, a chaperone with thiol-dependent reductase activity involved in MHC class I assembly. Embo J 1998;17:2186-95
14. Ortmann B, Copeman J, Lehner PJ, et al. A critical role for tapasin in the assembly and function of multimeric MHC class I-TAP complexes. Science 1997;277:1306-9
15. Fruh K, Gruhler A, Krishna RM, Schoenhals GJ. A comparison of viral immune escape strategies targeting the MHC class I assembly pathway. Immunol Rev 1999;168:157-66
16. Spriggs MK. One step ahead of the game: viral immunomodulatory molecules. Annu Rev Immunol 1996;14:101-30
17. Khanna R, Burrows SR, Steigerwald-Mullen PM, et al. Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance. Virology 1995;214:633-7
18. Levitskaya J, Sharipo A, Leonchiks A, et al. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci U S A 1997;94:12616-21
19. Murray RJ, Kurilla MG, Griffin HM, et al. Human cytotoxic T-cell responses against Epstein-Barr virus nuclear antigens demonstrated by using recombinant vaccinia viruses. Proc Natl Acad Sci U S A 1990;87:2906-10
20. Khanna R, Burrows SR, Kurilla MG, et al. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med 1992;176:169-76
21. Sharipo A, Imreh M, Leonchiks A, et al. A minimal glycine-alanine repeat prevents the interaction of ubiquitinated IkappaB alpha with the proteasome: a new mechanism for selective inhibition of proteolysis Nat Med 1998;4:939-44
22. Leonchiks A, Liepinsh E, Barishev M, et al. Random coil conformation of a Gly/Ala-rich insert in IkappaB alpha excludes structural stabilization as the mechanism for protection against proteasomal degradation. FEBS Lett 1998;40:365-9
23. Gilbert MJ, Riddell SR, Li CR, Greenberg PD. Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus. J Virol 1993;67:3461-9
24. Jahn G, Scholl BC, Traupe B, Fleckenstein B. The two major structural phosphoproteins (pp65 and pp150) of human cytomegalovirus and their antigenic properties. J Gen Virol 1987;68:1327-37
25. Ruger B, Klages S, Walla B, et al. Primary structure and transcription of the genes coding for the two virion phosphoproteins pp65 and pp71 of human cytomegalovirus. J Virol 1987;61:446-53
26. Gilbert MJ, Riddell SR, Plachter B, Greenberg PD. Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Nature 1996;383:720-2
27. York IA, Roop C, Andrews DW, et al. A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. Cell 1994;77: 525-35
28. Hill A, Jugovic P, York I, et al. Herpes simplex virus turns off the TAP to evade host immunity. Nature 1995;375:411-5
29. Fruh K, Ahn K, Djaballah H, et al. A viral inhibitor of peptide transporters for antigen presentation. Nature 1995;375:415-8
30. Galocha B, Hill A, Barnett BC, et al. The active site of ICP47, a herpes simplex virus-encoded inhibitor of the major histocompatibility complex (MHC)-encoded peptide transporter associated with antigen processing (TAP), maps to the NH2-terminal 35 residues. J Exp Med 1997;185:1565-72
31. Ahn K, Meyer TH, Uebel S, et al. Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47. Embo J 1996;15: 3247-55
32. Lacaille VG, Androlewicz MJ. Herpes simplex virus inhibitor ICP47 destabilizes the transporter associated with antigen processing (TAP) heterodimer. J Biol Chem 1998;273:17386-90
33. Jugovic P, Hill AM, Tomazin R, et al. Inhibition of major histocompatibility complex class I antigen presentation in pig and primate cells by herpes simplex virus type 1 and 2 ICP47. J Virol 1998;72: 5076-84
34. Tomazin R, van Schoot NE, Goldsmith K, et al. Herpes simplex virus type 2ICP47 inhibits human TAP but not mouse TAR J Virol 1998;72:2560-3
35. Hengel H, Flohr T, Hammerling GJ, et al. Human cytomegalovirus inhibits peptide translocation into the endoplasmic reticulum for MHC class I assembly. J Gen Virol 1996;77:2287-96
36. Hengel H, Koopmann JO, Flohr T, et al. A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter. Immunity 1997;6:623-32
37. Ahn K, Gruhler A, Galocha B, et al. The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity 1997;6:613-21
38. Lehner PJ, Karttunen JT, Wilkinson GW, Cresswell P. The human cytomegalovirus US6 glycoprotein inhibits transporter associated with antigen processing-dependent peptide translocation. Proc Natl Acad Sci U S A 1997;94:6904-9
39. Burgert HG, Kvist S. The E3/19K protein of adenovirus type 2 binds to the domains of histocompatibility antigens required for CTL recognition. Embo J 1987;6:2019-26
40. Jefferies WA, Burgert HG. E3/19K from adenovirus 2 is an immunosubversive protein that binds to a structural motif regulating the intracellular transport of major histocompatibility complex class I proteins. J Exp Med 1990;172:1653-64
41. Beier DC, Cox JH, Vining DR, et al. Association of human class I MHC alleles with the adenovirus E3/19K protein. J Immunol 1994;152:3862-72
42. Paabo S, Bhat BM, Wold WS, Peterson PA. A short sequence in the COOH-terminus makes an adenovirus membrane glycoprotein a resident of the endoplasmic reticulum. Cell 1987;50:311-7
43. Cox JH, Bennink JR, Yewdell JW. Retention of adenovirus E19 glycoprotein in the endoplasmic reticulum is essential to its ability to block antigen presentation. J Exp Med 1991;174:1629-37
44. Jackson MR, Nilsson T, Peterson PA. Identification of a consensus motif for retention of transmembrane proteins in the endoplasmic reticulum. Embo J 1990;9:3153-62
45. Bennett EM, Bennink JR, Yewdell JW, Brodsky FM. Cutting edge: adenovirus E19 has two mechanisms for affecting class I MHC expression. J Immunol 1999;162:5049-52
46. Ahn K, Angulo A, Ghazal P, et al. Human cytomegalovirus inhibits antigen presentation by a sequential multistep process. Proc Natl Acad Sci U S A 1996;93:10990-5
47. Jones TR, Wiertz EJ, Sun L, et al. Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proc Natl Acad Sci U S A 1996;93:11327-33
48. Schust DJ, Tortorella D, Seebach J, et al. Trophoblast class I major histocompatibility complex (MHC) products are resistant to rapid degradation imposed by the human cytomegalovirus (HCMV) gene products US2 and US11. J Exp Med 1998; 188:497-503
49. Wiertz EJ, Tortorella D, Bogyo M, et al. Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature 1996;384:432-8
50. Wiertz EJHJ, Jones TR, Sun L, et al. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell 1996;84:769-79
51. Tortorella D, Story CM, Huppa JB, et al. Dislocation of type I membrane proteins from the ER to the cytosol is sensitive to changes in redox potential [published erratum appears in J Cell Biol 1999; 145(3):following 642]. J Cell Biol 1998;142:365-76
52. Tortorella D, Story CM, Huppa JB, et al. Dislocation of type I membrane proteins from the ER to the cytosol is sensitive to changes in redox potential [published erratum appears in J Cell Biol 1999; 145(3):following 642]. J Cell Biol 1998;142:365-76
53. Bankier AT, Beck S, Bohni R, et al. The DNA sequence of the human cytomegalovirus genome. DNA Seq 1991;2:1-12
54. Story CM, Furman MH, Ploegh HL. The cytosolic tail of class I MHC heavy chain is required for its dislocation by the human cytomegalovirus US2 and US11 gene products. Proc Natl Acad Sci U S A 1999;96:8516-21
55. Shamu CE, Story CM, Rapoport TA, Ploegh HL. The pathway of USII-dependent degradation of MHC class I heavy chains involves a ubiquitin-conjugated intermediate. J Cell Biol 1999;147:45-58
56. Plemper RK, Wolf DH. Retrograde protein translocation: Eradication of secretory proteins in health and disease. Trends Biochem Sci 1999;24:266-70
57. Ziegler H, Thale R, Lucin P, et al. A mouse cytomegalovirus glycoprotein retains MHC class I complexes in the ERGIC/cis-Golgi compartments. Immunity 199;6:57-66
58. Reusch U, Muranyi W, Lucin P, et al. A cytomegalovirus glycoprotein re-routes MHC class I complexes to lysosomes for degradation. Embo J 1999;18:1081-91
59. Kleijnen MF, Huppa JB, Lucin P, et al. A mouse cytomegalovirus glycoprotein, gp34, forms a complex with folded class I MHC molecules in the ER which is not retained but is transported to the cell surface. Embo J 1997;16:685-94
60. Schwartz O, Marechal V, Le Gall S, et al. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med 1996;2:338-42
61. Kerkau T, Bacik I, Bennink JR, et al. The human immunodeficiency virus type 1 (HIV-1) Vpu protein interferes with an early step in the biosynthesis of major histocompatibility complex (MHC) class I molecules. J Exp Med 1997;185:1295-305
62. Le Gall S, Erdtmann L, Benichou S, et al. Nef interacts with the mu subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules. Immunity 1998;8:483-95
63. Cohen GB, Gandhi RT, Davis DM, et al. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 1999;10:661-71
64. Collins KL, Chen BK, Kalams SA, et al HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 1998;391: 397-401
65. Greenberg ME, Iafrate AJ, Skowronski J. The SH3 domain-binding surface and an acidic motif in HIV-1 Nef regulate trafficking of class IMHC complexes. Embo J 1998;17:2777-89
66. Mangasarian A, Piguet V, Wang JK, et al. Nef-induced CD4 and major histocompatibility complex class I (MHC-I) down-regulation are governed by distinct determinants: N-terminal alpha helix and proline repeat of Nef selectively regulate MHC-I trafficking. J Virol 1999;73:1964-73
67. Riggs NL, Craig HM, Pandori MW, Guatelli JC. The dileucine-based sorting motif in HIV-1 Nef is not required for down-regulation of class I MHC. Virology 1999;258:203-7